Commercialising leukemia and lymphoma therapies - future challenges
Ibrutinib and ublituximab – a promising combination regimen for treating CLL?
Current research into drug treatments for CLL - specifically ibrutinib, idelalisib and venetoclax
Novel adoptive transfer mouse models in CLL
Elisa ten Hacken
Recent developments in the mutational landscape and molecular basis of AML